Sudhir Srivastava

18.0k total citations · 2 hit papers
142 papers, 8.9k citations indexed

About

Sudhir Srivastava is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Sudhir Srivastava has authored 142 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Molecular Biology, 49 papers in Oncology and 46 papers in Cancer Research. Recurrent topics in Sudhir Srivastava's work include Cancer Genomics and Diagnostics (35 papers), Pancreatic and Hepatic Oncology Research (25 papers) and Prostate Cancer Treatment and Research (20 papers). Sudhir Srivastava is often cited by papers focused on Cancer Genomics and Diagnostics (35 papers), Pancreatic and Hepatic Oncology Research (25 papers) and Prostate Cancer Treatment and Research (20 papers). Sudhir Srivastava collaborates with scholars based in United States, Malaysia and Canada. Sudhir Srivastava's co-authors include David Sidransky, C. Richard Boland, Randall W. Burt, Stephen J. Meltzer, Stanley R. Hamilton, Riccardo Fodde, Guglielmina Nadia Ranzani, Stephen N. Thibodeau, Miguel A. Rodrı́guez-Bigas and James R. Eshleman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature reviews. Cancer.

In The Last Decade

Sudhir Srivastava

140 papers receiving 8.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

1998 3.3k citations Sudhir Srivastava et al. PubMed profile →
Addressing overdiagnosis and overtreatment in cancer: a prescription for change

2014 351 citations Sudhir Srivastava et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sudhir Srivastava United States	41	3.6k	3.4k	3.3k	2.7k	1.5k	142	8.9k
Michael S. Sabel United States	51	3.8k 1.1×	3.0k 0.9×	1.4k 0.4×	2.7k 1.0×	987 0.7×	174	8.8k
Apostolia M. Tsimberidou United States	58	5.4k 1.5×	4.8k 1.4×	3.4k 1.0×	4.2k 1.6×	3.3k 2.2×	445	14.5k
Gary M. Tse Hong Kong	57	3.6k 1.0×	2.4k 0.7×	3.5k 1.1×	3.4k 1.3×	1.7k 1.2×	324	11.4k
Timothy J. Yeatman United States	56	5.1k 1.4×	5.9k 1.7×	2.1k 0.6×	2.9k 1.1×	1.6k 1.1×	169	11.8k
Silvia Marsoni Italy	42	4.8k 1.3×	2.3k 0.7×	2.5k 0.7×	2.5k 0.9×	2.2k 1.4×	156	8.3k
Frédéric Bibeau France	49	6.3k 1.8×	3.3k 1.0×	2.5k 0.7×	3.0k 1.1×	2.4k 1.6×	193	10.7k
Anthony Lucci United States	56	5.5k 1.5×	3.2k 0.9×	2.3k 0.7×	6.1k 2.3×	1.2k 0.8×	254	11.3k
Randall E. Brand United States	54	5.6k 1.6×	3.2k 0.9×	1.9k 0.6×	2.4k 0.9×	1.1k 0.7×	253	9.8k
Daniel W. Visscher United States	58	4.7k 1.3×	2.6k 0.8×	3.2k 1.0×	4.3k 1.6×	1.6k 1.1×	228	11.0k
Andreas Hochhaus Germany	87	7.3k 2.1×	6.1k 1.8×	3.1k 0.9×	1.9k 0.7×	2.7k 1.8×	839	40.0k

Countries citing papers authored by Sudhir Srivastava

Since Specialization

Citations

This map shows the geographic impact of Sudhir Srivastava's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sudhir Srivastava with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sudhir Srivastava more than expected).

Fields of papers citing papers by Sudhir Srivastava

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sudhir Srivastava. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sudhir Srivastava. The network helps show where Sudhir Srivastava may publish in the future.

Co-authorship network of co-authors of Sudhir Srivastava

This figure shows the co-authorship network connecting the top 25 collaborators of Sudhir Srivastava. A scholar is included among the top collaborators of Sudhir Srivastava based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sudhir Srivastava. Sudhir Srivastava is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tang, Tiffany M., Yuping Zhang, Javed Siddiqui, et al.. (2025). A simplified MyProstateScore2.0 for high-grade prostate cancer. Cancer Biomarkers. 42(1). 453481555–453481555.

Wagner, Paul D. & Sudhir Srivastava. (2023). National Cancer Institute's early detection research network: a model organization for biomarker research. SHILAP Revista de lepidopterología. 3(2). 93–99. 5 indexed citations

Srivastava, Sudhir, et al.. (2023). PreCancer Atlas: Present and Future. Cancer Prevention Research. 16(7). 379–384. 10 indexed citations

Etzioni, Ruth, Roman Gulati, Christos Patriotis, et al.. (2023). Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies. JNCI Journal of the National Cancer Institute. 116(2). 189–193. 14 indexed citations

Minasian, Lori M., Paul F. Pinsky, Hormuzd A. Katki, et al.. (2022). Study design considerations for trials to evaluate multicancer early detection assays for clinical utility. JNCI Journal of the National Cancer Institute. 115(3). 250–257. 36 indexed citations

Chari, Suresh T., Anirban Maitra, Lynn M. Matrisian, et al.. (2021). Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma. Contemporary Clinical Trials. 113. 106659–106659. 31 indexed citations

Kwong, Gabriel A., Sharmistha Ghosh, Lena Gamboa, et al.. (2021). Synthetic biomarkers: a twenty-first century path to early cancer detection. Nature reviews. Cancer. 21(10). 655–668. 130 indexed citations

Dai, Jianliang, Neehar D. Parikh, Myron Schwartz, et al.. (2018). Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute’s Early Detection Research Network. Contemporary Clinical Trials. 76. 49–54. 18 indexed citations

Kenner, Barbara, Suresh T. Chari, Anirban Maitra, et al.. (2016). Early Detection of Pancreatic Cancer—a Defined Future Using Lessons From Other Cancers. Pancreas. 45(8). 1073–1079. 50 indexed citations

10.

Wang, Mengjun, Karthik Devarajan, Amit G. Singal, et al.. (2015). The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma. Cancer Prevention Research. 9(2). 172–179. 53 indexed citations

11.

Rastogi, Anshu, Shyh‐Han Tan, Shashwat Sharad, et al.. (2014). ERG Monoclonal Antibody in the Diagnosis and Biological Stratification of Prostate Cancer: Delineation of Minimal Epitope, Critical Residues for Binding, and Molecular Basis of Specificity. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 33(4). 201–208. 4 indexed citations

12.

Srivastava, Sudhir, et al.. (2008). Translational Research Working Group Developmental Pathway for Biospecimen-Based Assessment Modalities. Clinical Cancer Research. 14(18). 5672–5677. 24 indexed citations

13.

Baird, Cheryl L., Keith D. Miller, David Apiyo, et al.. (2008). Immobilization strategies for single‐chain antibody microarrays. PROTEOMICS. 8(11). 2199–2210. 21 indexed citations

14.

Yan, Xiao, Xiugong Gao, Gallya Gannot, et al.. (2008). Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection. International Journal of Cancer. 122(10). 2178–2186. 45 indexed citations

15.

Singh, Gyanendra, Neeraj Sinha, Sharad Sharma, & Sudhir Srivastava. (2004). Histological changes due to in vitro exposure of cyclophosphamide in post implantation rat embryos. Indian Journal of Veterinary Pathology. 28(2). 118–120. 1 indexed citations

16.

Maruvada, Padma & Sudhir Srivastava. (2004). Biomarkers for Cancer Diagnosis: Implications for Nutritional Research. Journal of Nutrition. 134(6). 1640S–1645S. 12 indexed citations

17.

Hine, R. Jean, Sudhir Srivastava, John A. Milner, & Sharon A. Ross. (2003). Nutritional Links to Plausible Mechanisms Underlying Pancreatic Cancer: A Conference Report. Pancreas. 27(4). 356–366. 15 indexed citations

18.

Zullo, Steven J., et al.. (2002). Nanotechnology: Emerging Developments and Early Detection of Cancer. A Two‐Day Workshop Sponsored by the National Cancer Institute and the National Institute of Standards and Technology, August 30–31 2001, on the National Institute of Standards and Technology Campus, Gaithersburg, MD, USA. Disease Markers. 18(4). 153–158. 2 indexed citations

19.

Myers, Russell B., David A. Brown, Denise K. Oelschlager, et al.. (1996). Elevated serum levels of p105erbB-2 in patients with advanced-stage prostatic adenocarcinoma. International Journal of Cancer. 69(5). 398–402. 25 indexed citations

20.

Grizzle, William E., et al.. (1994). Evaluation of biomarkers in breast and prostate cancer.. PubMed. 19. 259–66. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact